3
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
30
Carcinoma, Hepatocellular
17
Ovarian Neoplasms
14
Fallopian Tube Neoplasms
10
Carcinoma, Non-Small-Cell Lung
9
Neoplasms
8
Glioblastoma
7
Liver Neoplasms
6
Lung Neoplasms
5
Colonic Neoplasms
5
Breast Neoplasms
5
Neoplasm Metastasis
4
Carcinoma, Renal Cell
4
Brain Neoplasms
4
Stomach Neoplasms
3
Rectal Neoplasms
3
Melanoma
3
Carcinoma, Ovarian Epithelial
3
Carcinoma
3
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Nasopharyngeal Neoplasms
2
Nasopharyngeal Carcinoma
2
Lymphoid Interstitial Pneumonia
2
Colorectal Cancer Metastatic
2
Brenner Tumor
2
Advanced Solid Tumors
2
Adenocarcinoma, Mucinous
2
Virus Diseases
1
Interventions
tremelimumab
1
durvalumab
1
atezolizumab
1
Bumetanide
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Unresectable Hepatocellular Carcinoma
×
Bevacizumab
×
Clear all
NCT06117891
2026-05-12
REFINE-IO
Bayer
Active not recruiting
300 enrolled